Rocket One Inc. RKTO

RKTO Company Overview

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for dermatological, oncology, and inflammatory diseases. The company operates within the biotechnology and life sciences industry, with a strategy centered on in-licensing and advancing early-stage drug candidates addressing unmet medical needs. Hoth Therapeutics does not currently generate product revenue and is primarily funded through equity financing to support research and development activities.

The company’s pipeline includes multiple product candidates targeting conditions such as atopic dermatitis, cutaneous T-cell lymphoma, acne, and cancer-related toxicities. Hoth’s strategic positioning emphasizes topical and localized therapies designed to reduce systemic side effects, which the company views as a potential competitive advantage. Hoth Therapeutics was incorporated in 2017 and became a publicly traded company through an initial public offering in 2020, trading on the Nasdaq Capital Market under the ticker symbol HOTH.